Atuliflapon
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Atuliflapon
- Structure (SMILES)
These details could not be displayed.
- atuliflapon
- Atuliflapon
- atuliflapon [INN]
- Atuliflapon [WHO-DD]
- atuliflapon inn
- atuliflapon who dd
- azd 5718
- Azd 5718
- AZD-5718
- azd5718
- Azd5718
- AZD5718
- AZD5718 IR tablet
- AZD5718 oral suspension
- CAS registry numbers
- 2041075-86-7
- ChEMBL ID
- CHEMBL4802195
- InChIKey
- ROTWSDMXHVGAHZ-QZTJIDSGSA-N
- PubChem compound IDs
- 122678117
- FDA ingredient codes (UNII)
- NV6352Y6TV
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- AZD5718
- Type
- Synthetic organic
- Drug name stem
- -flapon
Mechanisms of action
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- 5-LOX activating protein
- Gene symbol
- 5-LOX activating protein
- Median affinity
- 8.2
- Affinity units
- pIC50
- Condition
- Cardiovascular Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000319
- Subject identifier
- D002318
- Condition
- Coronary Disease
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001645
- Subject identifier
- D003327
- Condition
- Renal Insufficiency, Chronic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003884
- Subject identifier
- D051436
- Condition
- Acute Coronary Syndrome
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005672
- Subject identifier
- D054058
- Condition identifier
- EFO_0000319
- Highest recorded phase
- 1
- Condition identifier
- EFO_0001645
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003884
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005672
- Highest recorded phase
- 2
- Condition identifier
- EFO_0008585
- Highest recorded phase
- 2
- Condition identifier
- EFO_0008586
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004979
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005010
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005016
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005068
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005542
- Highest recorded phase
- 2
- NCT02632526
- NCT03948451
- NCT04492709
- NCT02963116
- NCT03317002
- NCT03400488
- NCT03420092
- NCT04087187
- NCT04210388
- NCT04492722
- NCT04734275
- NCT04601467
- Calculated partition coefficient (XLogP)
- 2.5
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Heavy atoms
- 33
- Monoisotopic mass
- 446.20663871
- Natural product
- No
- Recorded assays
- 111
- Active assays
- 6
Active assay types
- Confirmatory
Related records
Trials (12)
- A Study to Assess the Amount of Drug Levels in Blood and Safety of AZD5718 Formulations in Healthy Volunteers
- A Study to Assess the Bioavailability of Different Formulations of AZD5718 and the Food Effect on the Selected Formulation of AZD5718 in Healthy Volunteers
- A Study to Assess the Effect of Multiple Doses of AZD5718 on Pharmacokinetics of Oral Midazolam in Healthy Subjects
- A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Japanese Men
- A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects
- A Study to Estimate the Effect of AZD5718 on the Pharmacokinetics (What Does the Body Does to the Drug) of Rosuvastatin to Measure the Relative Bioavailability (the Extent to Which a Drug or Other Substance Becomes Available to the Body) of AZD5718 Oral Suspension vs AZD5718 Immediate Release Tablet
- A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease
- AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD).
- PASSIvation of Vulnerable Plaque With AZD5718 in AcuTe Coronary syndromE
- Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD5718 in Volunteers
- Study to Assess Relative Bioavailability and Safety of AZD5718 in Healthy Volunteers
- Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma
In development for (5)
- Acute coronary syndrome Phase 2
- Asthma Phase 2
- Cardiovascular disorder Phase 1
- Chronic kidney disease Phase 2
- Coronary artery disorder Phase 2